Gene · 51592
Papers2,289
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,289
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Age-dependent myositis-specific autoantibody profiles and CD8+ T-cell signatures in juvenile dermatomyositis. | Immunol Med | 2026 | 42808692 | PubTator, text mining | PubMed |
| Transcriptional intermediary factor 1 gamma-based multitarget gene therapeutic strategy for triple-negative breast cancer. | Signal Transduct Target Ther | 2026 | 42805968 | PubTator, text mining | PubMed |
| The TIF-1γ autoantigen in patients with dermatomyositis and thyroid cancer: from case series to preliminary mechanistic exploration. | Front Immunol | 2026 | 42774280 | PubTator, text mining | PubMed |
| Catching up with calcinosis: analysis of clinical characteristics, myositis-specific autoantibodies, and response to therapy in juvenile dermatomyositis. | Clin Exp Rheumatol | 2026 | 42752384 | PubTator, text mining | PubMed |
Multicenter Clinical Comparison Between Anti-NXP2 and Anti-TIF1-γ Antibody-Positive Myositis, and Analysis of the Clinical Significance of Anti-NXP2 Antibody Titers in Idiopathic Inflammatory Myopathies. | J Dermatol | 2026 | 42750350 | PubTator, text mining | PubMed |
| Upadacitinib for refractory cutaneous disease in a patient with tif1γ-positive dermatomyositis. | An Bras Dermatol | 2026 | 42696844 | PubTator, text mining | PubMed |
| Clinical characteristics, organ damage and survival in idiopathic inflammatory myopathies: a long-term retrospective cohort study. | Rheumatol Int | 2026 | 42667319 | PubTator, text mining | PubMed |
| A five-factor risk-stratification model for cancer-associated myositis in idiopathic inflammatory myopathies and stage-specific survival analysis: a multicentre Japanese MYKO cohort study. | Front Immunol | 2026 | 42643601 | PubTator, text mining | PubMed |
| Proteomic Signatures and an Injury-Stress Endotype in Myositis-Associated Interstitial Lung Disease. | medRxiv | 2026 | 42620435 | PubTator, text mining | PubMed |
| TIF1γ holds the line against regulatory T cell plasticity. | Nat Immunol | 2026 | 42601472 | PubTator, text mining | PubMed |
| Cancer-associated myositis in Chinese patients with idiopathic inflammatory myopathies: Malignancy spectrum, risk factors, and validation of the IMACS guideline. | Semin Arthritis Rheum | 2026 | 42585765 | PubTator, text mining | PubMed |
| TIF1γ regulates stability of regulatory T cells during inflammation. | Nat Immunol | 2026 | 42581187 | PubTator, text mining | PubMed |
| Cancer-associated myositis: a single-centre 20-year experience. | Clin Rheumatol | 2026 | 42579256 | PubTator, text mining | PubMed |
| Yorkie/YAP Interactors: Fine-Tuning the Hippo Pathway Output. | Cold Spring Harb Perspect Biol | 2026 | 42575696 | PubTator, text mining | PubMed |
| Primary Cutaneous Gamma-Delta T-Cell Lymphoma Complicating Long-Standing Immunosuppressed Dermatomyositis. | J Cutan Pathol | 2026 | 42550017 | PubTator, text mining | PubMed |
| Magnetic resonance imaging changes of thigh muscles in dermatomyositis patients with anti-Mi2 antibody. | Ann Med | 2026 | 42538838 | PubTator, text mining | PubMed |
| Perioperative management of anti-TIF1-γ dermatomyositis in a patient with breast cancer: a case report. | Front Med (Lausanne) | 2026 | 42487969 | PubTator, text mining | PubMed |
| Anti-transcription Intermediary Factor-1 Gamma Antibody-positive Dermatomyositis with Interstitial Lung Disease and Multisystem Involvement: A Case Report. | Ann Afr Med | 2026 | 42487305 | PubTator, text mining | PubMed |
| Breast cancer radiotherapy in patients with autoimmune or cancer-associated myositis: balancing oncological benefit and immune-mediated risk. | Radiat Oncol | 2026 | 42464399 | PubTator, text mining | PubMed |
| Multicentre international audit of IMACS malignancy screening guidelines in idiopathic inflammatory myopathies: insights from the myositis audit and research collaborative group. | RMD Open | 2026 | 42457211 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51592/papers